| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
DigitalML works with large enterprises to guide them along the road to digital market leadership, enabling IT modernization, digital innovation, all while supporting governance, regulation & compliance. Our ignite platform is unique to the market; offering an active holistic catalog of APIs, Services, and Events with extended lifecycle management. A partner, not just a vendor, for your digital maturity journey across mindset, process, and tooling.
Lacework provides end-to-end cloud security automation for AWS, Azure, and GCP with a comprehensive view of risks across cloud workloads and containers.
Silicon Valley World Internet Center is a Palo Alto, CA-based company in the Software and Internet sector.
KatalystDI is a technology company that provides software solutions for optimizing construction supply chains and implementing offsite, modular, and other supply chain centric initiatives.